Novartis

14 stories · 4 sources · updated every week

Novartis's $12 billion Avidity acquisition is in question after pelacarsen and del-desiran failed Phase 3 trials on September 8th, wiping out $30 billion in market value by September 11th. Investors are demanding board accountability; watch for responses from Novartis leadership and ongoing pressure regarding acquisition strategy.

Novartis

Timeline

Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution

Pharma Revives Osteoporosis Drug Development

STAT+: Radiopharma companies merge after one receives surprise FDA rejection

How Did a Heart Drug With So Much Promise Fall So Flat?

STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more

STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field

Why Two Heart Drug Trials Failed: Novo Nordisk, Novartis

STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more

Amgen Drops 7% as Novartis Heart Drug Trial Fails

Novartis stock sinks 12.5% as del-desiran flunks Phase 3

STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more

Novartis Pelacarsen Miss Rattles Lp(a) Drug Race

STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company

STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more

STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study

STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more

Experts Push for Bolder Radiopharmaceutical Dosing

STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?

Novartis leads Lp(a) drug race as treatments near market

FDA Rejects ITM Therapy; Hims & Hers Eyes Peptides

Shows up with